Influence of dietary supplementation of short‐chain fatty acid sodium propionate in people living with HIV (PLHIV)

作者：Vesta Brauckmann, Smita Nambiar, Anja Potthoff, S. Höxtermann, Janet Wach, Arne Kayser, Carsten Tiemann, Ann-Kathrin Schuppe, N Brockmeyer, Adriane Skaletz‐Rorowski · 发表于：Journal of the European Academy of Dermatology and Venereology · 年份：2022 · DOI：10.1111/jdv.18006 · 被引用次数：20 · 研究领域：Gut microbiota and health、HIV-related health complications and treatments、Nutritional Studies and Diet

BACKGROUND: Non-AIDS-associated chronic diseases in HIV+ patients have been on the rise since the advent of antiretroviral therapy. Especially cardiovascular diseases and disruption in the gastrointestinal tract have limited health-related quality of life (QoL). Several of those complications have been associated with chronic systemic inflammation. Short-chain fatty acids (SCFA), with propionate as one of the major compounds, have been described as an important link between gut microbiota and the immune system, defining the pro- and the anti-inflammatory milieu through direct and indirect regulation of T-cell homeostasis. The effects of dietary supplementation of sodium propionate (SP) in people living with HIV (PLHIV) have not yet been investigated prior to this study. OBJECTIVES: To investigate the impact of SP uptake among PLHIV and its relevance to improve QoL, the study aimed to investigate metabolic, immunological, microbiome and patient-reported QoL-related changes post-SP supplementation with follow-up. METHODS: A prospective, non-randomized, controlled, monocentric interventional study was conducted in WIR, Center for Sexual Health and Medicine, in Bochum, Germany. 32 HIV+ patients with unaltered ART-regimen in the last three months were included. Participants were given SP for a duration of 12 weeks in the form of daily oral supplementation and were additionally followed-up for another 12 weeks. RESULTS: The supplementation of SP was well tolerated. We found an impr...